Cost-effectiveness of nivolumab compared with surveillance for adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in France

被引：0

作者：

Sylvie Negrier ^{[1
]}

Julia Bonastre ^{[2
]}

Florian Colrat ^{[3
]}

Siguroli Teitsson ^{[4
]}

Christopher Knight ^{[5
]}

Lei Ni ^{[6
]}

Julie Chevalier ^{[6
]}

Sébastien Branchoux ^{[7
]}

Morgan Rouprêt ^{[4
]}

机构：

[1] Department of Medical Oncology, Centre Léon Bérard, Université Claude Bernard Lyon 1, Lyon

[2] Biostatistics and Epidemiology, Institut Gustave Roussy Cancer Campus, Villejuif

[3] INSERM, Université Paris-Saclay, CESP U1018 Oncostat, Labelisé Ligue Contre le Cancer, Villejuif

[4] Department of Health Economics and Outcome Research, Bristol-Myers Squibb, Rueil-Malmaison

[5] Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge

[6] RTI Health Solutions, Manchester

[7] VYOO, Paris

[8] Sorbonne Université GRC 5 Predictive Onco-Uro, Urology Department, AP-HP, Hôpital Pitié- Salpêtrière, Paris

来源：

World Journal of Urology | / 43卷 / 1期

关键词：

Adjuvant treatment; Cost-effectiveness; Cost-utility; Economic evaluation; Immune checkpoint inhibitor; Nivolumab; Urothelial carcinoma;

D O I：

10.1007/s00345-025-05589-2

中图分类号：

学科分类号：

摘要：

Purpose: To evaluate the cost-effectiveness of nivolumab for adjuvant treatment of adults with muscle-invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) and tumour cell expression PD-L1 ≥ 1% following radical resection from the payer perspective in France. Methods: A four-state (disease-free, loco-regional recurrence, distant recurrence, death) semi-Markov model was developed to simulate health outcomes and costs in a cohort of patients with MIUC-HR and tumour cell expression PD-L1 ≥ 1% following radical resection. Health state-specific costs and quality of life-adjusted life years (QALYs) were compared between two treatment strategies (nivolumab, surveillance). The time horizon was 15 years. Clinical and utility inputs were modelled from the data obtained in the Phase III trial CheckMate 274 (#NCT02632409). Cost inputs were extracted from French sources (notably the French National Cost Study). Model outputs were life-years and QALYs overall and by health-state, total costs and cost components. The incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) between the two treatment strategies were calculated. Results: Life-years were 7.3 for nivolumab and 5.2 for surveillance; QALYs were 4.7 for nivolumab and 3.3 for surveillance. The between-strategy difference in QALYs was essentially accrued in the disease-free state (nivolumab: 4.2, surveillance: 2.6). Total costs were €129,150 for nivolumab and €93,031 for surveillance. The principal cost components were nivolumab acquisition (€ 44,054) and disease management (nivolumab: €29,831; surveillance: €27,233). The estimated ICER was € 17,228/LY gained and the estimated ICUR was €25,806/QALY. Conclusion: Nivolumab in the adjuvant setting is likely to be cost-effective compared to surveillance in France. © The Author(s) 2025.

引用

共 28 条

[1] Huang A.C., Zappasodi R., A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance, Nat Immunol, 23, 5, pp. 660-670, (2022)
[2] Shiravand Y., Khodadadi F., Kashani S.M.A., Hosseini-Fard S.R., Hosseini S., Sadeghirad H., Ladwa R., O'Byrne K., Kulasinghe A., Immune checkpoint inhibitors in cancer therapy, Curr Oncol, 29, 5, pp. 3044-3060, (2022)
[3] Bajorin D.F., Witjes J.A., Gschwend J.E., Schenker M., Valderrama B.P., Tomita Y., Bamias A., Lebret T., Shariat S.F., Park S.H., Ye D., Agerbaek M., Enting D., McDermott R., Gajate P., Peer A., Milowsky M.I., Nosov A., Neif Antonio J., Tupikowski K., Toms L., Fischer B.S., Qureshi A., Collette S., Unsal-Kacmaz K., Broughton E., Zardavas D., Koon H.B., Galsky M.D., Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma, N Engl J Med, 384, 22, pp. 2102-2114, (2021)
[4] Sante H.A.D., Methodological guidance. Choices in methods for economic evaluation
[5] Husereau D., Drummond M., Augustovski F., de Bekker-Grob E., Briggs A.H., Carswell C., Caulley L., Chaiyakunapruk N., Greenberg D., Loder E., Mauskopf J., Mullins C.D., Petrou S., Pwu R.F., Staniszewska S., Force C.I.G.R.P.T., Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations, Value Health, 25, 1, pp. 3-9, (2022)
[6] Latimer N.R., Survival analysis for economic evaluations alongside clinical trials–extrapolation with patient-level data: inconsistencies, limitations, and a practical guide, Med Decis Mak, 33, 6, pp. 743-754, (2013)
[7] Fraslin A., Colrat F.P., Karimi M., Bonastre J., Karine G., Teitsson S., Prudent A., Branchoux S., Radvanyi F., Benhamou S., Allory Y., Lebret T., Characteristics, management and survival outcomes of French patients (pts) with muscle invasive bladder cancer (MIBC) at high risk of recurrence (MIBC-HR): A study based on the coblance cohort, Ann Oncol, 33, (2022)
[8] Lebret T., Bonastre J., Fraslin A., Neuzillet Y., Droupy S., Rebillard X., Vordos D., Guy L., Villers A., Schneider M., Coloby P., Lacoste J., Mejean A., Lacoste J., Descotes J.L., Eschwege P., Loison G., Blanche H., Mariani O., Ghaleh B., Mangin A., Sirab N., Groussard K., Radvanyi F., Allory Y., Benhamou S., Cohort profile: coblance: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and
[9] Witjes J.A., Bruins H.M., Cathomas R., Comperat E.M., Cowan N.C., Gakis G., Hernandez V., Linares Espinos E., Lorch A., Neuzillet Y., Rouanne M., Thalmann G.N., Veskimae E., Ribal M.J., van der Heijden A.G., European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines, Eur Urol, 79, 1, pp. 82-104, (2021)
[10] Roupret M., Xylinas E., Colin P., Houede N., Comperat E., Audenet F., Larre S., Masson-Lecomte A., Pignot G., Brunelle S., Roumiguie M., Neuzillet Y., Mejean A., [French CcAFU guidelines - Update 2018–2020: upper tract urothelial carcinoma], Prog Urol, 28, pp. R34-R47, (2018)

← 1 2 3 →